Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized study comparing the efficacy and safety of two doses of thalidomide (100 mg/day versus 400 mg/day) in the treatment of subjects with refractory or relapsed multiple myeloma

Next Previous
Trial Profile

Multicenter, randomized study comparing the efficacy and safety of two doses of thalidomide (100 mg/day versus 400 mg/day) in the treatment of subjects with refractory or relapsed multiple myeloma

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Thalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation

Most Recent Events

  • 22 Oct 2019 Route and form of Thalidomide assumed fom RDI.
  • 07 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top